רווח תפעולי לפני ניכוי פחת: Theratechnologies (THTX)

The automation of HIV drug synthesis accelerates development but requires expert involvement. The consolidated EBITDA reflects cash flow volatility, with the current level sitting around . Patent protection and stringent FDA oversight create barriers to entry for competitors, while the digitalization of distribution monitoring via contract platforms optimizes logistics for Theratechnologies Inc. (THTX).

This indicator measures net cash flow from operating activities before depreciation and interest, determining the business's fundamental ability to generate liquidity for scaling. Analysis of the EBITDA_Co chart on the GURU.Markets platform allows for an assessment of the financial stability of Theratechnologies Inc. (THTX), whose profits are supported by high margins on orphan drugs for HIV patients and protection against competitive pricing pressure.